Evidence map›Paper›PMID 27255080›Full record

Trial reportTrials2016

Effectiveness of a medication-adherence tool: study protocol for a randomized controlled trial.

Mirrian Hilbink, Joyca Lacroix, Linda Bremer-van der Heiden, Aart van Halteren, Martina Teichert, Jan van Lieshout

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mirrian HilbinkRadboud University Medical Center, Radboud Institute for Health Sciences, IQ healthcare, PO box 9101, Code: 114 IQ healthcare, 6500 HB, Nijmegen, The Netherlands.
Joyca LacroixBehavior, Cognition & Perception, Philips Research, Eindhoven, The Netherlands.
Linda Bremer-van der HeidenBehavior, Cognition & Perception, Philips Research, Eindhoven, The Netherlands.
Aart van HalterenBehavior, Cognition & Perception, Philips Research, Eindhoven, The Netherlands.
Martina TeichertRadboud University Medical Center, Radboud Institute for Health Sciences, IQ healthcare, PO box 9101, Code: 114 IQ healthcare, 6500 HB, Nijmegen, The Netherlands.
Jan van LieshoutRadboud University Medical Center, Radboud Institute for Health Sciences, IQ healthcare, PO box 9101, Code: 114 IQ healthcare, 6500 HB, Nijmegen, The Netherlands. Jan.vanLieshout@radboudumc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundResearch shows that more than half of the people taking medication for a chronic condition are non-adherent. Nonadherence hinders disease control with a burden on patient quality of life and healthcare systems. We developed a tool that provides insight into nonadherence risks and barriers for medication-adherence including an intervention strategy to overcome those barriers. This study aims to assess the effectiveness of using this adherence tool in starters with cardiovascular or oral blood glucose-lowering medication to improve medication-adherence. METHODS/

designIn a cluster-randomized controlled trial 25 pharmacies in the Netherlands will be randomized to the intervention or control arm. Patients registered in a general practice participating in a collaborative can be included when they start cardiovascular or oral blood glucose-lowering medication prescribed by their general practitioner. Participants complete an assessment consisting of measuring nonadherence risk and potential barriers to adherence. For patients with an increased nonadherence risk, a graphic barrier profile is created, showing to what extent eight cognitive, emotional, or practical barriers are present. All patients will fill in the medication-adherence assessment twice: between 1 and 2 weeks after the start of the medication and after 8 months. The intervention strategy consists of discussing this barrier profile to overcome barriers. Pharmacists and assistants of the intervention pharmacies are trained in discussing the profile and to offer a tailored intervention to overcome barriers. In the control arm, patients receive care as usual. The primary outcome is medication-adherence of patients with a high risk of nonadherence at 8 months follow-up. Secondary outcomes include the difference in the percentage of patients with an increased nonadherence risk between intervention and control group after 8 months, the predictive values of the baseline questionnaire in the control group in relation to medication-adherence after 8 months, medication-adherence after 1 year follow-up, and barriers and facilitators in the implementation of the tool. DISCUSSION: This manuscript presents the protocol for a cluster-randomized clinical trial on the use of an adherence tool to improve medication-adherence. This study will provide insight into the effectiveness of the tool in starters with cardiovascular or oral blood glucose-lowering medication in improvement of medication-adherence.

trial registrationThe Netherlands National Trial Register, NTR5186 . Registered on 18 May 2015.

Indexed as

Community Pharmacy ServicesMedication AdherencePharmacistsSurveys and QuestionnairesAdministration, OralBiomarkersBlood GlucoseCardiovascular AgentsCardiovascular DiseasesCognitionDiabetes MellitusEmotionsHealth Knowledge, Attitudes, PracticeHumansHypoglycemic AgentsNetherlandsBiomarkersBlood GlucoseCardiovascular AgentsHypoglycemic AgentsBarriersCardiovascular diseasesDiabetesMedication adherencePrimary care

Identifiers

PMID27255080
PMCPMC4891916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.